XML 64 R41.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Reconciliation of Segment Information to Total Consolidated Information
Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.
(In millions)
Generics
Segment
 
Specialty
Segment
 
Corporate /
Other(1)
 
Consolidated
Year Ended December 31, 2015
 
 
 
 
 
 
 
Total revenues
 
 
 
 
 
 
 
Third party
$
8,198.6

 
$
1,230.7

 
$
—

 
$
9,429.3

Intersegment
6.3

 
10.9

 
(17.2
)
 
—

Total
$
8,204.9

 
$
1,241.6

 
$
(17.2
)
 
$
9,429.3

 
 
 
 
 
 
 
 
Segment profitability
$
2,555.8

 
$
670.5

 
$
(1,765.4
)
 
$
1,460.9

 
Year Ended December 31, 2014
 
 
 
 
 
 
 
Total revenues
 
 
 
 
 
 
 
Third party
$
6,510.4

 
$
1,209.2

 
$
—

 
$
7,719.6

Intersegment
4.7

 
9.0

 
(13.8
)
 
—

Total
$
6,515.2

 
$
1,218.2

 
$
(13.8
)
 
$
7,719.6

 
 
 
 
 
 
 
 
Segment profitability
$
1,870.3

 
$
664.5

 
$
(1,182.2
)
 
$
1,352.6

Year Ended December 31, 2013
 
 
 
 
 
 
 
Total revenues
 
 
 
 
 
 
 
Third party
$
5,900.6

 
$
1,008.5

 
$
—

 
$
6,909.1

Intersegment
5.7

 
19.3

 
(25.0
)
 
—

Total
$
5,906.3

 
$
1,027.8

 
$
(25.0
)
 
$
6,909.1

 
 
 
 
 
 
 
 
Segment profitability
$
1,656.3

 
$
461.6

 
$
(982.4
)
 
$
1,135.5

____________
(1) 
Includes certain corporate general and administrative and R&D expenses; litigation settlements, net; certain intercompany transactions, including eliminations; amortization of intangible assets and certain purchase accounting items; impairment charges; and other expenses not directly attributable to segments.
Net Third Party Sales Classified Based on Therapeutic Product Categories
The Company’s net sales are generated via the sale of products in the following therapeutic categories:
 
 
Year Ended December 31,
(In millions)
2015
 
2014
 
2013
Allergy
$
1,010.8

 
$
1,017.5

 
$
850.2

Anti-infectives
1,380.0

 
1,264.4

 
1,080.3

Cardiovascular
1,167.7

 
955.9

 
1,162.3

Central Nervous System
1,690.8

 
1,318.6

 
1,393.3

Dermatological
215.4

 
223.8

 
247.9

Endocrine and Metabolic
1,165.6

 
778.7

 
568.3

Gastrointestinal
761.6

 
344.6

 
365.8

Renal and Genitourinary Agents
395.7

 
609.5

 
191.1

Respiratory System
442.2

 
252.3

 
259.7

Other(1)
1,132.8

 
881.2

 
737.7

 
$
9,362.6

 
$
7,646.5

 
$
6,856.6

____________
(1) 
Other consists of numerous therapeutic classes, none of which individually exceeds 5% of consolidated net sales.
Net Third Party Sales Classified Based on Geographic Location of Customers
At January 1, 2014, the regions within the Generic Segment were recast to North America, Europe, and Rest of World, which are the Company’s principal geographic markets. Net sales are classified based on the geographic location of our subsidiaries and are as follows:
 
 
Year Ended December 31,
(In millions)
2015
 
2014
 
2013
North America
 
 
 
 
 
United States
$
4,848.9

 
$
4,425.3

 
$
3,866.8

Other
251.5

 
123.1

 
121.5

Europe
 
 
 
 
 
The Netherlands (1)
66.5

 
61.1

 
57.1

Other (2)
2,139.1

 
1,415.7

 
1,372.6

Rest of World (3)
2,056.6

 
1,621.3

 
1,438.6

 
$
9,362.6

 
$
7,646.5

 
$
6,856.6

____________
(1) 
Mylan N.V. is domiciled in the Netherlands.
(2) 
Net sales from France consisted of approximately 8%, 9% and 10% of consolidated net sales for the years ended December 31, 2015, 2014 and 2013, respectively.
(3) 
Net sales from India consisted of approximately 11%, 12% and 11% of consolidated net sales for the years ended December 31, 2015, 2014 and 2013, respectively.